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Abstract
Organic nitrates, such as nitroglycerin, are commonly used in the therapy of cardiovascular
disease. Long-term therapy with these drugs, however, results in the rapid development of
nitrate tolerance, limiting their hemodynamic and anti-ischemic efficacy. In addition, nitrate
tolerance is associated with the expression of potentially deleterious modifications such as
increased oxidative stress, endothelial dysfunction, and sympathetic activation. In this review
we discuss current concepts regarding the mechanisms of organic nitrate bioactivation, nitrate
tolerance, and nitrate-mediated oxidative stress and endothelial dysfunction. We also examine
how hydralazine may prevent nitrate tolerance and related endothelial dysfunction. (Cardiol J
2009; 16: 11–19)
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Introduction
Organic nitrates, such as nitroglycerin (GTN,
glycerol trinitrate), isosorbide dinitrate (ISDN), iso-
sorbide mononitrate (ISMN), and pentaerithrityl
tetranitrate (PETN), are commonly used in clinical
cardiovascular medicine in the acute treatment of
stable-effort angina, unstable angina, acute myocar-
dial infarction, chronic congestive heart failure,
pulmonary oedema, and severe arterial hyperten-
sion. The development of tolerance, i.e. the reduc-
tion in vasodilatatory effect or the requirement of
higher doses that appear after continuous use, is
a major factor limiting the efficacy of these drugs.
Although intermittent nitrate therapy, which allows
a daily nitrate washout interval, has been effective
in the prevention of nitrate tolerance, this regimen
is limited by its inability to provide a continuous and
uninterrupted therapeutic effect [1–3].
Experimental and clinical investigations sug-
gest that GTN-, ISDN-, and ISMN-induced toleran-
ce is associated with the expression of potentially
deleterious modifications such as increased oxida-
tive stress, endothelial dysfunction, and sympathe-
tic activation [4–6]. Therefore, there is increasing
awareness of the fact that nitrate tolerance cannot
simply be viewed as a loss of the beneficial effects
of nitrate but also as a condition potentially media-
ting extra harmful consequences [7].
The exact mechanisms of nitrate bioactivation
and the development of nitrate tolerance and nitrate-
-induced oxidative stress, endothelial dysfunction,
and sympathetic activation are not completely un-
derstood [4, 8–10]. It is therefore not surprising that
various strategies proposed for the prevention of
nitrate tolerance, perhaps with the exception of hy-
dralazine, have not proven particularly clinically
beneficial. Hydralazine is a direct-acting smooth
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muscle relaxant with strong antioxidative proper-
ties, which, given simultaneously with nitrate, ef-
fectively prevents the development of oxidative
stress and nitrate tolerance in experimental and
clinical settings [8]. Chronic treatment with a com-
bination of hydralazine and ISDN has been shown
to have beneficial effects on left ventricular func-
tion and survival in patients with severe heart fa-
ilure [11–13]. This clinical success of the chronic
co-administration of nitrate and this antioxidant gi-
ves the prospect of a more effective means of chro-
nic medication with organic nitrates. In this review
we discuss current concepts on the mechanisms of
nitrate bioactivation and tolerance. We also exami-
ne how hydralazine may prevent nitrate tolerance
and endothelial dysfunction.
Basic pharmacology of organic nitrates
The beneficial clinical effects of GTN and other
organic nitrates are due to preferential dilation of
large conductance veins and large arteries while
arterioles are dilated only by much higher concen-
trations of nitrates [14–16]. Low doses of organic
nitrates cause peripheral venodilation, with redistri-
bution of circulating blood volume away from the
heart and lungs and toward the splanchnic and me-
senteric circulation. The resulting reduction in pre-
load is manifested by a decrease in cardiac cham-
ber size, ventricular filling pressure and wall ten-
sion, and systemic blood pressure. Cardiac output
in the normal heart may fall in response to nitrate
administration, whereas cardiac output and stroke
volume may show a modest rise in patients with left
ventricular impairment.
Nitrates also induce arterial vasodilation that
becomes progressively more marked with incre-
asing dose and plasma concentration. Only at high
plasma nitrate concentrations does arteriolar vaso-
dilation occur. The increased arterial conductance
and related decrease in peripheral vascular resistan-
ce lead to a reduction in left ventricular afterload.
The reduction in right and left ventricular pre-
load and afterload caused by nitrate decreases car-
diac work and lowers myocardial oxygen require-
ments. As a result, the ratio of myocardial oxygen
demand to myocardial oxygen supply improves, and
myocardial ischemia is alleviated or prevented.
A nitrate-induced increase in myocardial corona-
ry flow (oxygen supply) is another important compo-
nent of the anti-ischemic activity of these drugs. The
effects of nitrates on coronary circulation include:
— improvement in the subendocardial/subepicar-
dial blood flow ratio; the mechanism of effort-
-angina involves an exercise-induced increase
in subepicardial coronary flow and a simulta-
neous decrease in the subendocardial flow in
the heart muscle territory supplied by the ste-
notic coronary artery [17]. This redistribution
of flow from endocardium to epicardium is at-
tenuated or prevented by organic nitrates;
— prevention or reversal of coronary artery va-
soconstriction — spontaneous or precipitated
by exercise; eccentric atherosclerotic lesions
with a rim or arc of intact vascular smooth
muscle remaining in the arterial wall are capa-
ble of contraction and relaxation, and parado-
xical vasospasm of this region is often precipi-
tated by exercise. Coronary artery relaxation
induced by organic nitrates may increase the
calibre of these stenoses, thereby decreasing
resistance across the obstruction and impro-
ving the coronary flow;
— dilatation of coronary collateral vessels.
In addition to vascular action, organic nitrates
have antiaggregatory properties in patients with
stable and unstable angina.
In summary, it is believed that the combina-
tion of increased supply and decreased demand of
oxygen is a unique therapeutic benefit of organic
nitrates in cardiac ischemia. In addition, because of
their hemodynamic profile, nitrates may be particu-
larly useful in patients with angina who have impa-
ired left ventricular systolic function or heart failure.
GTN and other nitrates function as prodrugs
that, when bioactivated, release nitric oxide (NO)
or S-nitrosothiol in vascular smooth muscle and
endothelial cells. This nitrate-derived NO eventu-
ally supplements endothelial production of NO. In
this sense, nitrates are endothelium-independent
vasodilators that are not reliant on functioning en-
dothelium for their vasodilator activity. It is belie-
ved, therefore, that the same downstream cellular
mechanism accounts for the vasorelaxant bioactivi-
ty of organic nitrates, vasorelaxation by endothelium-
dependent vasodilators (agonists like acetylcholine
that stimulate endothelial NO formation) and by di-
rect NO donors (e.g. nitroprusside), and for the ba-
sal endothelium-dependent vasodilatory tone pre-
sent in the vasculature (Fig. 1, right-hand side).
Thus, NO activates an intracellular NO recep-
tor enzyme, soluble guanylyl cyclase (sGC), incre-
asing tissue levels of the second messenger cyclic
3’5’-guanosine monophosphate (cGMP). This re-
sults in the activation of cGMP-dependent protein
kinase (PKG) and cGMP-gated ion channels. The
phosphorylation of target proteins by PKG eventu-
ally mediates smooth muscle relaxation and other
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cellular effects. The mechanism of vasodilation in-
cludes cGMP- and PKG-mediated attenuation of an
agonist-mediated rise in intracellular Ca2+ levels
and desensitization of contractile proteins to Ca2+
in smooth muscle cells [4, 18]. This hypothesis on
sGC-cGMP-PKG vascular signalling pathways of ni-
trates is supported by the findings that the inhibi-
tion of NO-sensitive sGC attenuates nitrate-media-
ted vasorelaxation and that the inhibition of pho-
sphodiesterases that degrade cGMP increases the
vasorelaxation potency of nitrates [4, 9, 19].
Bioactivation of organic nitrates
Pathways that are of a degrading and activating
nature metabolize organic nitrates. It is believed
that the bioactivation routes involve the production
of glycerol-1,2-dinitrate, inorganic nitrite, and finally
S-nitrosothiols and NO (Fig. 2). There has been an
extensive search for the nonenzymatic and enzy-
matic reactions catalyzing GTN bioactivation and
several candidates have been proposed, including
thiol-supported GTN bioactivation, GSH-S-transfe-
rase, cytochrome P450, cytochrome P450 reducta-
se, and xanthine oxidase [4, 10]. However, none of
these enzymatic pathways appears to satisfactorily
explain the therapeutic activity of organic nitrates,
as they all require concentrations of nitrates appro-
ximately 3–4 orders of magnitude higher than tho-
se reached in plasma during most clinical applica-
tions (100–1000 mM range vs. < 50 nM measured
in patients [4, 19]).
Recently Chen at al. [20] provided evidence
that the mitochondrial isoform of aldehyde dehydro-
genase (ALDH-2 or mtALDH) is responsible for the
bioactivation of GTN. The authors demonstrated
Figure 1. Biological effects accompanying biotransformation of nitroglycerine (GTN). Right-hand side: GTN is bio-
transformed by mitochondrial aldehyde dehydrogenase (mtALDH) to release nitric oxide (NO), and NO activates
sGC-cGMP-PKG signal transduction mechanism to produce vasodilation. The same vasodilation transduction me-
chanism is used by factors that activate endothelial NO synthase (eNOS) and increase endothelial NO formation by
this enzyme. Shear stress-mediated activation of eNOS and related basal NO production maintain a basal endothe-
lium-dependent vasodilator tone in the vasculature. Endothelial receptor activation and related eNOS stimulation
and NO production account for vasodilation produced by a number of agonists. Left-hand side: Simultaneously,
GTN uncouples the mitochondrial respiratory chain to increase mitochondrial superoxide anion production (O2–).
This results in the activation of membrane-bound nicotinamide adenine dinucleotide phosphate (NADPH) oxidase.
O2– produced by this enzyme causes a number of adverse effects, which include endothelial and autonomic dysfunc-
tion, and oxidation of a critical thiol group in the active site of mtALDH, resulting in impaired GTN biotransformation
and nitrate tolerance. For further explanation see text; sGC — soluble guanylyl cyclase; cGMP — cyclic guanosine-3’, 5’-
-monophosphate; PKG — cGMP activated protein kinase.
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that purified mtALDH specifically catalyses the for-
mation of 1,2-glycerol dinitrate and nitrite from
GTN (used in small clinically relevant concentra-
tions) (Fig. 2), that this reaction is supported by
various dithiols, that it mediates the production of
cGMP and the relaxation of vascular smooth musc-
le, and that all these effects of GTN are eliminated
by mtALDH inhibition or genetic deletion of
mtALDH [21]. These studies demonstrated that
mtALDH is necessary and sufficient for vasoacti-
vity derived from therapeutic levels of GTN. In this
context the authors have speculated that nitrite
generated within the mitochondria is metabolized
further to generate NO-based bioactivity by reduc-
tion to NO and/or by conversion to S-nitrosothiol
[19, 20] (Fig. 2). Indeed, it has recently been de-
monstrated that mtALDH catalyzed GTN conver-
sion leads to NO generation [9]. However, the exact
reaction mechanism of this mitochondrial NO pro-
duction, as well as the form in which NO bioactivity
is conveyed from mitochondria to cytosolic sGC,
remain unresolved [9, 19].
It has been demonstrated further that the inhibi-
tion of mtALDH results in the bioactivation inhibition
of GTN and PETN but not ISDN and ISMN, consi-
stent with the bioactivation of the isosorbide nitrova-
sodilators by a mtALDH independent pathway [22].
It is well known that GTN and ISDN can inhi-
bit mtALDH activity [23]. However, Chen et al. [20]
were the first to provide evidence that prolonged
treatment with GTN results in GTN tolerance and
simultaneous inhibition of mtALDH in vascular pre-
parations (Fig. 2), and that the inhibition of mtALDH
with various specific enzyme inhibitors results in
vascular GTN tolerance, indicating that attenuated
nitrate bioactivation by mtALDH underlines, at le-
ast partially, the induction of nitrate tolerance.
mtALDH and nitrate-alcohol interactions
mtALDH is a major enzyme in the detoxifica-
tion of acetylaldehyde produced during ethanol oxi-
dation (it catalyzes acetylaldehyde oxidation to form
acetic acid). About 40% of the East-Asian popula-
tion that expresses a low-activity mutant of
mtALDH (Glu487Lys) exhibits significantly lowe-
red alcohol tolerance (due to adverse effects of ace-
tylaldehyde accumulation) as well as decreased
sensitivity to nitroglycerin treatment [19, 24–26].
On the other hand, organic nitrate medication along
with alcohol consumption causes disulfiran-like re-
actions, including blurred vision, nausea, and flushing
of the face and neck. Disulfiran (Anticol) is an ALDH
inhibitor that is still approved in many countries as
a deterrent for the aversive pharmacotherapy of
alcohol dependence. Recently disulfiran has been de-
monstrated to induce GTN-tolerance and endothe-
lial dysfunction in healthy volunteers [27]. Altoge-
ther these observations imply that mtALDH plays
a role in GTN bioactivation also in humans.
Tolerance, cross-tolerance,
and tachyphylaxis to organic nitrates
The phenomenon of tolerance is characterized
by impaired responsiveness to the organic nitrate,
Figure 2. Cellular metabolism of low levels of nitrogly-
cerin (GTN) in blood vessels. A. Bioactivation routes of
GTN are catalyzed by mtALDH and yield 1,2-dinitrate
and nitrite, and result in generation of NO and/or
S-nitrosothiol, and in vasodilatory activity. Degradation
routes yield predominantly 1,3-dinitrate + nitrite, rather
than 1,2-dinitrate + nitrite; B. The overall reaction of
mtATDH catalyzed bioactivation of GTN. The reaction
involves the reduction of the nitrogen in the dissociated
nitrite (reductase activity of mfALDH). The electrons for
this reduction are provided by cysteine-thiols at the
active site of the enzyme that are thereby converted to
a disulfide. Thereby, the enzyme undergoes reversible
conversion from its reduced active form to its oxidized
inactive form. Reductase activity of mtALDH can be
restored by dithiol compounds, explaining why bioacti-
vation of nitrates is strongly dependent on thiol bioava-
ilability and why exogenous thiols prevent nitrate tole-
rance [9, 10, 19]. However, an oxidative attack of reacti-
ve oxygen species and reactive nitrogen species on
thiol components of mtALDH may result in irreversible
inhibition of the enzyme [10].
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which is, in turn, demonstrated by reduced nitrate-
induced vasodilatation, reduced nitrate-induced blo-
od pressure lowering effect, and/or attenuation of
nitrate-induced anti-ischemic effect. Nitrate-induced
tolerance to other endothelium dependent (e.g. ace-
tylcholine) and endothelium-independent nitrovaso-
dilators (e.g. nitroprusside) is termed cross-toleran-
ce. Tachyphylaxis denotes impaired nitrate potency
in response to short-term challenges of vessels, usu-
ally with a high concentration of nitrate [1–3].
The tolerance has been reported to occur within
1–3 days of continuous GTN treatment in patients
with acute myocardial infarction [28] stable-effort
angina, and chronic congestive heart failure [29].
Clinical studies have shown that signs of tole-
rance also develop with chronic administration of
ISDN and ISMN, and that both these drugs also in-
duced severe endothelial dysfunction and oxidati-
ve stress with chronic treatment [30, 31]. PETN
seems to be an exception among nitrates as it was re-
ported to produce continuous vasodilation without si-
gns of tolerance in rabbits [32] and in humans [33, 34].
In addition, in contrast to GTN, PETN caused ne-
ither oxidative stress in humans [34] nor endothe-
lial dysfunction in hypercholesterolemic rabbits [35].
It was suggested that these might be due to the
fact that PETN induces the antioxidant defence
protein heme oxygenase producing antioxidant
molecule bilibubin and the vasodilator carbon mo-
noxide [22].
Mechanism of nitrate tolerance
The mechanisms underlying the phenomenon
of nitrate tolerance are still poorly defined. Recent
animal and human studies indicate that increased
vascular production of superoxide anion (O2–) un-
derlies the mechanism of the tolerance. In addition,
short-term experimental and clinical investigations
suggest that oxidative stress associated with tole-
rance induced by nitrate causes potentially delete-
rious modifications such as endothelial dysfunction
and sympathetic activation, which partially add to
the mechanism of nitrate tolerance and can be vie-
wed as additional side-effects of organic nitrate the-
rapy [5–7].
Free radical hypothesis of nitrate tolerance
In 1995 Münzel at al. [36] were the first to re-
port that the sustained administration of GTN cau-
ses increased vascular formation of O2–. Later the
same group identified the mitochondria as a major
source of oxidative stress in tolerant animals [22, 37],
a finding confirmed by others [38]. These findings
led to the oxidative stress hypothesis of nitrate to-
lerance [4, 6–8, 10].
Recent evidence suggests that the mitochon-
drial respiratory chain is the primary source of the
nitrate-induced O2– overproduction in vessels, le-
ading to a subsequent activation of vascular nicoti-
namide adenine dinucleotide phosphate (NADPH)
oxidase, and that mostly NADPH oxidase-derived
O2– mediates nitrate tolerance and endothelial dys-
function (Fig. 1, left-hand side) [39].
The superoxide anion is normally scavenged by
various intracellular and extracellular mechanisms,
including the enzyme superoxide dismutase. Howe-
ver, in higher concentrations it can overcome the-
se mechanisms and rapidly react with NO (that pro-
duced by the endothelium and nitrate-derived) to
form strong oxidant peroxynitrite [40]. These re-
active oxygen species (ROS) are believed to cause
nitrate tolerance in at least 3 mechanisms [4, 9, 10]:
— formation of peroxynitrite may reduce the bio-
availability of nitrate-derived NO, impairing its
vasodilator activity (and of other nitrodilators);
— vascular oxidative stress may cause sGC and
PKG inhibition, leading to desensitization of
vasodilator signalling pathway of organic nitra-
tes and of other nitrovasodilators;
— mitochondrial ROS were shown to inactivate
mtALDH, suggesting that reduced bioactiva-
tion of nitrates may underlie, at least partially,
the mechanism of nitrate tolerance.
The oxidative stress hypothesis of nitrate to-
lerance is supported by numerous reports demon-
strating that the tolerance is prevented, or at least
ameliorated, by co-administration of various antio-
xidants (e.g., vitamin C, vitamin E, folic acid, beta-
-adrenergic antagonist carvedilol, the vasodilator
hydralazine) and interventions inhibiting NADPH
oxidase-dependent ROS formation (statins, ACE in-
hibitors, hydralazine and NADPH oxidase inhibitor
apocynin) [4, 8–10, 39]. Interestingly, all of these
antioxidative interventions are also known to pro-
tect against the endothelial dysfunction caused by
various oxidative stress-related cardiovascular
disorders [41, 42], providing strong evidence for
O2– -mediated inactivation of NO as a common me-
chanism of nitrate tolerance and endothelial dys-
function.
Nitrate-induced endothelial dysfunction
Impaired endothelium-dependent vasodilation,
as evidenced by impaired flow-mediated and/or ace-
tylcholine-mediated vasodilation and simultane-
ously preserved vasodilation to direct NO donor
(e.g. GTN or nitroprusside), is a hallmark of endo-
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thelial dysfunction. Continuous GTN treatment is
associated with oxygen-free radical induced worse-
ning of endothelial function in patients with coro-
nary artery disease [31, 43, 44] and even induction
of endothelial dysfunction in healthy subjects [45].
Endothelial dysfunction my be an important
deleterious complication of nitrate medication as it
is a major predictor of cardiac events in patients
with coronary artery disease [46–48] and heart fa-
ilure [49]. In this context, a meta-analysis of clini-
cal studies suggested that nitrate tolerance may
underline the increases in cardiac morbidity seen
with chronic nitrate use [50]. However, generally
there is scant evidence concerning the long-term
clinical outcome of nitrate therapy. This is mainly
because the largest studies of organic nitrates in the
setting of stable angina pectoris or in post-infarc-
tion patients (GISSI, ISIS) involved follow-up pe-
riods of only few weeks [7]. This emphasizes the
need for large-scale, controlled studies regarding
the efficacy and safety of chronic nitrate therapy in
coronary artery disease.
Neuro-hormonal counter-regulation
and autonomic dysfunction
Medication with any vasodilator (e.g., organic
nitrate, dihydropiridine calcium channel blocker,
hydralazine) may be associated with counter regu-
latory neurohormonal activation initiated by drop in
blood pressure, and related arterial baroreceptor
unloading. In the case of organic nitrates, this has
been demonstrated in patients with coronary heart
disease [51] heart failure [52] and healthy volunte-
ers [53] given GTN in doses producing a drop in
blood pressure. The reaction included increases in
blood levels of catecholamines [53], renin and al-
dosterone [51, 53], and vasopressin [51, 53]. Pro-
bably as a result of this neuro-hormonal stimulation,
GTN therapy is associated with water and sodium
retention, weight gain and a marked increase in in-
travascular volume (as evidenced by a decrease in
hematocrit), which counteract the blood pressure
and preload lowering effects of GTN [51, 53]. By
contrast, intermittent transdermal GTN therapy
was associated with a different pattern of hormonal
response (values tending to return to baseline le-
vels after the nitrate-free interval), a lack of sodium
retention, and no evidence of plasma volume expan-
sion [53].
The loss of the initial hypotensive response
after continuous, but not intermittent, GTN admini-
stration has been repeatedly reported as evidence
of the occurrence of GTN tolerance [53]. Currently
this phenomenon is termed nitrate pseudo-tolerance
because at the time when the nitrate hypotensive
response ceases the vascular responsiveness to ni-
trate-induced vasodilation is still preserved [4, 51].
Besides the early neuro-hormonal counter-re-
gulatory mechanism mediated by the initial blood
pressure drop, chronic GTN treatment also results
in persistent autonomic dysfunction that is evident
even after the normalization of blood pressure.
Thus, prolonged exposure to GTN has been shown
to shift the physiological balance between the sym-
pathetic and vagal nervous systems in the modula-
tion of cardiac heart rate and heart rate variability
towards a prevalence of the sympathetic system,
impairing baroreflex function, and heart rate varia-
bility [5]. Such modifications might have negative
prognostic implications as they have been associa-
ted with increased incidence of arrhythmias and
worse prognosis in patients with coronary artery
disease and heart failure [54].
It has been proposed that nitrate-mediated
autonomic dysfunction is caused by reduction of
endogenous NO availability and/or synthesis in the
central nervous system as a result of oxidative
stress caused by continuous treatment with nitra-
te, and that this process would be analogous to ab-
normalities in vascular endothelial NO metabolism.
NO synthesis in the brain stem appears to have
a chronic inhibitory effect on medullary areas mo-
dulating sympathetic outflow. This effect may be
lost with prolonged nitrate treatment and subsequ-
ent development of oxidative stress [5–7].
Co-administration of
hydralazine and nitrate
Hydralazine hydrochloride is a direct-acting
smooth muscle relaxant used to treat hypertension
by acting as a vasodilator primarily in arterioles. The
cellular mechanism of vasodilation by hydralazine
is not well known. Hydralazine is not used as a pri-
mary drug for treating hypertension because it eli-
cits a reflex sympathetic activation that, by incre-
asing heart rate and cardiac output, may cause my-
ocardial ischemia. Hydralazine may also increase
plasma renin concentration, resulting in fluid reten-
tion. In order to prevent these undesirable side ef-
fects, hydralazine is generally prescribed in combi-
nation with a beta-blocker and a diuretic [55].
While organic nitrates mainly dilate large ca-
pacitance veins and large conductance arteries,
hydralazine is a potent arteriolar dilator. Therefo-
re, the initial rationale for use of organic nitrates
and hydralazine in combination in heart failure was
their complementary hemodynamic effect caused by
17
Emila Klemenska, Andrzej Beręsewicz, Nitrate tolerance
www.cardiologyjournal.org
the predominant venodilatory and preload reducing
effect of nitrates and the arteriolar-dilatory and
afterload reducing effect of hydralazine. This hemo-
dynamic rationale was the basis for the Vasodilator
Heart Failure Trial (V-HeFT), which evaluated the
effect of the combination of ISDN and hydralazine
on the outcome of patients with chronic heart failu-
re [56, 57]. In the first part of that study the combi-
nation ISDN/hydralazine resulted in a significant
reduction in mortality compared with results in
patients treated with either placebo or prazosin [56].
The V-HeFT II study, designed to compare the ef-
fects of the ISDN/hydralazine combination with
ACE-inhibitor enalapril, revealed that enalapril had
a greater effect on survival than the combination
ISDN/hydralazine. However, the combination
ISDN/hydralazine improved exercise tolerance and
left ventricular ejection fraction more than enala-
pril in these patients [57]. More recently, a fixed
dose combination of ISDN/hydralazine added to
a standard background neurohormonal blockade has
been shown to decrease mortality, reduce the inci-
dence of first hospitalization for heart failure, and
improve quality of life in the African American He-
art Failure Trial (A-HeFT) [58, 59].
Hydralazine, similarly to organic nitrates, me-
diates counter regulatory neurohormonal activation,
as evidenced by increases in plasma catecholamines
and renin activity. Theoretically, this would be
expected to aggravate counter regulatory adjust-
ments to nitrate and worsen nitrate tolerance resul-
ting from frequent administration of ISDN [30, 31].
Nonetheless, hydralazine was shown to prevent
GNT tolerance in experimental models [60–62].
Furthermore, hydralazine co-administered with
GTN appeared to prevent early development of
GTN tolerance and resulted in a persistent GTN-
-mediated beneficial hemodynamic effect on syste-
mic and pulmonary artery and left ventricular fil-
ling pressure in patients with chronic systolic he-
art failure [63]. In addition, it has been reported that
hydralazine: inhibits vascular NADPH oxidase, pre-
vents nitrate-induced vascular O2– overproduction [62],
and normalizes impaired PKG and impaired
mtALDH activity in nitrate-tolerant vessels [64].
Therefore, the current belief is that hydralazine
prevents nitrate tolerance because it has strong
antioxidative properties, and that prevention of ni-
trate tolerance with hydralazine enables the main-
tenance of the favourable hemodynamic effects of
nitrates [8, 65]. However, hydralazine may offer an
additional therapeutic benefit inherent to hydrala-
zine antioxidant effects [64].
Summary
There is mounting evidence that systemic the-
rapy with GTN, ISDN, and ISMN, but not with
PETN, induces tolerance and endothelial dysfunc-
tion, and that these effects are a major limitation of
the therapy with these drugs. Mitochondrial ALDH
has recently been recognized as an enzyme that
bioactivates GTN and PETN to produce NO. ISDN
and ISMN seem to undergo bioactivation by an
mtALDH-independent pathway. Bioactivation of
GTN (and probably of ISDN and ISMN, but not of
PETN) also results in the uncoupling of the mito-
chondrial respiratory chain that leads to increased
mitochondrial O2– production, which further media-
tes the activation of NADPH oxidase and increased
O2– production by this enzyme. The most likely
mechanism of nitrate tolerance involves O2–-indu-
ced inhibition of mtALDH, scavenging of nitrate-
derived NO, and the inhibition of various steps in
NO vasodilator signalling pathway. Oxidative stress
also causes endothelial dysfunction and probably
sympathetic activation; two consequences that may
be an additional risk for patients who receive con-
tinuous nitrate medication to treat conditions such
as stable and unstable angina or heart failure. Ho-
wever, the prognostic effect of nitrates in stable
coronary artery disease has never been studied
systematically, and “early entry” therapy with ni-
trates does not significantly improve survival in
myocardial infarction although it increases the be-
neficial effects of the ACE-inhibitor enalapril by
50% [16]. By contrast, these toxic phenomena mi-
ght be offset by the use of drugs that have antioxi-
dant properties and/or prevent nitrate-induced oxy-
gen free radical production. This notion is suppor-
ted by clinical studies demonstrating the beneficial
effects of ISDN combined with hydralazine in pa-
tients with chronic heart disease.
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